Dave Mullarkey

Dave Mullarkey is the CEO of ClearNote Health, a San Diego company that reads the chemical edits on your DNA to catch deadly cancers before symptoms show. A life-sciences operator who has shepherded three diagnostics and sequencing companies through scale-ups and acquisitions - Ariosa to Roche, Omniome to PacBio - he now leads the team behind the Avantect epigenomic blood tests for pancreatic and multi-cancer detection.